Nkarta (NKTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 Jun, 2026Opening remarks and agenda
Meeting opened by CEO Paul Hastings, who introduced directors, officers, legal counsel, accounting firm, and inspector of elections.
Inspector of elections sworn in to oversee voting and ensure impartiality.
Agenda and rules of conduct made available to participants via the meeting platform.
Board and executive committee updates
Two class 3 directors, Ali Behbahani and Zachary Scheiner, were nominated for re-election to serve until 2029.
Shareholder proposals
Four items of business: election of directors, ratification of accounting firm, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes.
No other proposals or nominations were received in accordance with bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nkarta
- Q2 2026 net loss was $40.4M; $243.2M in cash expected to fund operations into 2029.NKTX
Q2 2026 - CD19-directed CAR-NK therapy advances in autoimmune trials, with data and strong cash runway ahead.NKTX
H.C. Wainwright 27th Annual Global Investment Conference - Allogeneic NK cell therapy trials advance in autoimmune diseases, with data updates expected this year.NKTX
TD Cowen 46th Annual Health Care Conference - Upcoming 2026 data will shape the future of CAR-NK therapy in autoimmune diseases.NKTX
H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Off-the-shelf NK cell therapy targets autoimmune diseases with promising safety and efficacy.NKTX
Corporate presentation - Net loss narrowed in Q1 2026 as clinical trials advanced and cash runway extends into 2029.NKTX
Q1 2026 - Board recommends approval of all proxy proposals, with strong governance and compensation oversight.NKTX
Proxy filing - Key votes include director elections, auditor ratification, and executive pay approval.NKTX
Proxy filing - Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway.NKTX
25th Annual Needham Virtual Healthcare Conference